Anesthesia and analgesia
-
Anesthesia and analgesia · Oct 2011
Comparative StudyThe effect of cross-training with adjustable airway model anatomies on laryngoscopy skill transfer.
A problem with learning endotracheal intubation on airway mannequins is poor transfer of direct laryngoscopy skills from model to patient. We developed an airway model with adjustable anatomic features and investigated whether practicing on a model with frequent adjustments improved laryngoscopy skills transfer. ⋯ The results verify that proficiency on one model does not guarantee success on another. However, subjects who trained with a laryngoscopy mannequin in multiple configurations did not show better skill transfer than subjects practicing on fixed configuration airway models.
-
Anesthesia and analgesia · Oct 2011
Randomized Controlled TrialNitrous oxide paradoxically modulates slow electroencephalogram oscillations: implications for anesthesia monitoring.
Anesthesia with nitrous oxide preserves awake features of the EEG leading to inappropriately higher BIS values.
pearl -
Anesthesia and analgesia · Oct 2011
Lidocaine attenuates the development of diabetic-induced tactile allodynia by inhibiting microglial activation.
Lidocaine is used clinically for tactile allodynia associated with diabetes-induced neuropathy. Although the analgesic effect of lidocaine through suppression of microglial activation has been implicated in the development of injury-induced neuropathic pain, its mechanism of action in diabetes-induced tactile allodynia has not yet been completely elucidated. ⋯ Lidocaine alleviates STZ-induced tactile allodynia, possibly by modulating the p38 pathway in spinal microglial cells. Inhibiting microglial activation by lidocaine treatment early in the course of diabetes-induced neuropathy represents a potential therapeutic strategy for tactile allodynia.
-
Anesthesia and analgesia · Oct 2011
Randomized Controlled TrialReversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study.
Clopidogrel (Plavix®) therapy, although effective for minimizing risk of thrombotic events, is also associated with potential bleeding risk. Recombinant activated FVII (rFVIIa, NovoSeven®) induces hemostasis in hemophilia patients with inhibitors (alloantibodies) and has been proposed as potential treatment for mitigating clopidogrel therapy-mediated bleeding. ⋯ In this clinical study, rFVIIa (10 and 20 μg/kg) reversed the effect of clopidogrel on blood loss.